Évian-les-Bains

EVIAN AND COPERNI ANNOUNCE AN ASTRONOMICAL-INSPIRED NEW COLLABORATION

Retrieved on: 
Monday, November 13, 2023
Beach House, Creativity, Georges Pompidou, Imagination, Beauty, Soho House, Culture, TAO, Science, Movement, Viviparity, Nicolaus Copernicus, Partnership, Water, Soho House (club), Centre Pompidou, Évian-les-Bains, Restaurant, Fashion design, Nightclub, Bottled water

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Today, evian® reveals its latest designer collaboration with Coperni, the pioneering luxury fashion brand known for combining technical innovation with Parisian refinement.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Today, evian® reveals its latest designer collaboration with Coperni, the pioneering luxury fashion brand known for combining technical innovation with Parisian refinement.
  • At the heart of the constellation lies a depiction of the iconic source of evian water at Evian Les Bains.
  • In addition to the campaign films, evian and Coperni are activating the launch in major local markets where the two iconic brands will showcase the collaboration amongst key industry & media figures.
  • Leeni Hämäläinen, North America Marketing Director, evian, says: 'At evian, we believe that innovation, imagination, and artistry have the power to unlock extraordinary experiences.

Poxel Announces its Participation at Upcoming Scientific Conferences Related to Adrenoleukodystrophy (ALD)

Retrieved on: 
Monday, September 27, 2021
Research, Diabetes, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, HSCT, Man, Sex linkage, Weakness, Senior, Metabolism, Peroxisome, Death, Growth, POC, Cell, Incontinence, Scientific communication, ALD, Euronext Paris, Lists of diseases, NASH, Disease, Peripheral nervous system, AMN, VLCFA, Conditional sentence, Fatty liver disease, Pharmacology, Metabolic disorder, Exocrine gland, Partnership, Évian-les-Bains, Degenerative disease, White matter, ABCD1, Spinal cord, Company, Adrenoleukodystrophy, Woman, Risk, Gait, Brain, Haemophilia, R, Forward-looking statement, Doctor of Philosophy, Treatment, Chronic inflammatory demyelinating polyneuropathy, Nervous system, Sumitomo Dainippon Pharma, Euronext, Patient, Hematopoietic stem cell transplantation, Hotel manager, AMPK, Prevalence, Pharmaceutical industry, Medical device, ALD, Poxel SA, ALD, POXEL SA

POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.

Key Points: 
  • POXEL SA (Euronext POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies.
  • Poxel's scientific team will present data and plans pertaining to ALD that align with the recently announced new strategic direction of increasing Poxels focus on rare metabolic diseases.
  • Poxel is committed to focus its pipeline on high value, rare metabolic indications and NASH, with the goal of creating pipeline synergies, maximizing resources, and driving shareholder value.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.